Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04633278
Title CMP-001 in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Checkmate Pharmaceuticals
Indications

hypopharynx cancer

oral squamous cell carcinoma

head and neck squamous cell carcinoma

oropharynx cancer

laryngeal squamous cell carcinoma

Therapies

Pembrolizumab + Vidutolimod

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.